BB
BB Biotech Portfolio holdings
AUM
$3.98B
This Quarter Return
-15.67%
1 Year Return
+15.06%
3 Year Return
+120.36%
5 Year Return
+263.74%
10 Year Return
–
AUM
$3.15B
AUM Growth
+$3.15B
(-15%)
Cap. Flow
+$183M
Cap. Flow
% of AUM
5.82%
Top 10 Holdings %
Top 10 Hldgs %
73.8%
Holding
31
New
2
Increased
20
Reduced
2
Closed
3
Top Buys
| 1 |
MDVN
MEDIVATION, INC.
MDVN
|
$54.8M |
| 2 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$40.2M |
| 3 |
JUNO
Juno Therapeutics, Inc.
JUNO
|
$34.8M |
| 4 |
Ionis Pharmaceuticals
IONS
|
$28.5M |
| 5 |
RDUS
Radius Health, Inc.
RDUS
|
$24.3M |
Top Sells
| 1 |
RCPT
RECEPTOS INC COM STK (DE)
RCPT
|
$126M |
| 2 |
Innoviva
INVA
|
$5.99M |
| 3 |
Theravance Biopharma
TBPH
|
$4.68M |
| 4 |
Neurocrine Biosciences
NBIX
|
$1.99M |
| 5 |
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
|
$187K |
Sector Composition
| 1 | Healthcare | 83.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Incyte
INCY
$16.5B
| $414M | 13.12% |
3,750,406
+10,000
| +0.3% | +$1.1M |
|
|
CELG
2
DELISTED
Celgene Corp
CELG
| $388M | 12.31% |
3,589,298
+25,000
| +0.7% | +$2.7M |
|
|
RDUS
3
DELISTED
Radius Health, Inc.
RDUS
| $296M | 9.39% |
4,272,140
+350,000
| +9% | +$24.3M |
|
4
Gilead Sciences
GILD
$140B
| $272M | 8.64% |
2,774,596
+59,000
| +2% | +$5.79M |
|
|
5
Ionis Pharmaceuticals
IONS
$6.79B
| $268M | 8.5% |
6,634,838
+705,412
| +12% | +$28.5M |
|
|
ALXN
6
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $162M | 5.13% |
1,034,428
+257,000
| +33% | +$40.2M |
|
7
Agios Pharmaceuticals
AGIO
$2.19B
| $149M | 4.72% |
2,109,921
+120,000
| +6% | +$8.47M |
|
8
Vertex Pharmaceuticals
VRTX
$100B
| $142M | 4.51% |
1,365,445
+31,000
| +2% | +$3.23M |
|
|
9
Neurocrine Biosciences
NBIX
$13.8B
| $126M | 4% |
3,171,552
-50,000
| -2% | -$1.99M |
|
|
MDVN
10
DELISTED
MEDIVATION, INC.
MDVN
| $110M | 3.48% |
2,581,112
+1,290,556
| +100% | +$54.8M |
|
11
Regeneron Pharmaceuticals
REGN
$61.5B
| $95.4M | 3.02% |
205,000
+7,000
| +4% | +$3.26M |
|
12
Halozyme
HALO
$8.56B
| $93.1M | 2.95% |
6,929,832
+852,664
| +14% | +$11.5M |
|
13
Alnylam Pharmaceuticals
ALNY
$58.5B
| $91M | 2.89% |
1,132,499
+167,000
| +17% | +$13.4M |
|
14
Novavax
NVAX
$1.21B
| $58.9M | 1.87% |
8,330,000
+150,000
| +2% | +$1.06M |
|
|
CLVS
15
DELISTED
Clovis Oncology, Inc.
CLVS
| $56.8M | 1.8% |
618,188
| – | – |
|
|
JUNO
16
DELISTED
Juno Therapeutics, Inc.
JUNO
| $53.1M | 1.68% |
1,305,000
+855,000
| +190% | +$34.8M |
|
|
CEMP
17
DELISTED
Cempra, Inc.
CEMP
| $52.7M | 1.67% |
1,891,900
+125,000
| +7% | +$3.48M |
|
|
ALDR
18
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $49.5M | 1.57% |
1,510,150
+355,000
| +31% | +$11.6M |
|
|
TSRO
19
DELISTED
TESARO, Inc.
TSRO
| $46.3M | 1.47% |
1,154,582
+250,000
| +28% | +$10M |
|
|
KITE
20
DELISTED
Kite Pharma, Inc.
KITE
| $41.8M | 1.32% |
750,000
+400,000
| +114% | +$22.3M |
|
21
Puma Biotechnology
PBYI
$254M
| $39.3M | 1.25% |
521,991
| – | – |
|
|
ICPT
22
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $35M | 1.11% |
210,719
+30,000
| +17% | +$4.98M |
|
23
PTC Therapeutics
PTCT
$3.92B
| $34.8M | 1.1% |
1,302,912
+50,000
| +4% | +$1.34M |
|
|
INFI
24
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $22.8M | 0.72% |
2,700,737
| – | – |
|
25
Esperion Therapeutics
ESPR
$448M
| $21.4M | 0.68% |
+908,542
| New | +$21.4M |
|